The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.

doi:10.1111/j.1365-2125.1991.tb05594.x

Back to search

Article

The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.

British journal of clinical pharmacology - 1 Jun 1991

Ward S A, Helsby N A, Skjelbo E, Brøsen K, Gram L F, Breckenridge A M

Abstract excerpt

The activation of the antimalarial drug proguanil (PG) to the active metabolite cycloguanil (CG) has been evaluated in a panel of 18 subjects. These subjects had previously been screened and classified as mephenytoin poor (PMm) or extensive metabolisers (EMm) and sparteine poor (PMs) or extensive...

Topics

Adult
Female
Humans
Male
Mephenytoin
Oxidation-Reduction
Phenotype
Polymorphism, Genetic
Proguanil
Reference Values
Sparteine
Triazines

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.